Loading clinical trials...
Loading clinical trials...
Application of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Conditions
Interventions
anti Tim-3/CD123 CAR-T cell therapy
Locations
1
China
Kailin Xu
Xuzhou, Jiangsu, China
Start Date
November 4, 2023
Primary Completion Date
January 1, 2026
Completion Date
January 1, 2027
Last Updated
November 9, 2023
NCT04716452
NCT06459024
NCT06297941
NCT05190471
NCT06532084
NCT05506332
Lead Sponsor
Xuzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions